SCHEMBL4363225

SCHEMBL4363225

CCc1nc2cc(C)cc(C)c2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 5/20 0.54
▸ KMT2A Q03164 4/20 0.44
▸ GAA P10253 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ ADORA3 P0DMS8 4/20 0.42
▸ ADORA2A P29274 3/20 0.42
▸ DDAH1 O94760 1/20 0.42
▸ TNKS2 Q9H2K2 1/20 0.38
▸ GRIN2D O15399 1/20 0.36
▸ GRIN3B O60391 1/20 0.36
▸ GRIN1 Q05586 1/20 0.36
▸ GRIN2A Q12879 1/20 0.36
▸ GRIN2B Q13224 1/20 0.36
▸ GRIN2C Q14957 1/20 0.36
▸ GRIN3A Q8TCU5 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ MAPT P10636 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ PSMD14 O00487 1/20 0.36
▸ MMP2 P08253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13907870 0.86 KMT2A (0.40) ADORA1KMT2AADORA3ADORA2AGRIN2D
SCHEMBL1918902 0.82 ADORA1 (0.51) ADORA1KMT2AGAAHTTADORA3
SCHEMBL13907881 0.81 NPC1 (0.37) ADORA1KMT2AGRIN2DGRIN3BGRIN1
SCHEMBL13907874 0.80 CACNA1H (0.37) ADORA1KMT2AGRIN2DGRIN3BGRIN1
SCHEMBL11749723 0.80 TSHR (0.36) ADORA1KMT2AGAAGRIN2DGRIN3B
SCHEMBL10439086 0.78 KMT2A (0.43) ADORA1KMT2AMAPTMEN1TDP1
SCHEMBL13907876 0.78 IDO1 (0.43) ADORA1KMT2AADORA2AGRIN2DGRIN3B
SCHEMBL13907878 0.78 CACNA1H (0.38) ADORA1KMT2AGRIN2DGRIN3BGRIN1
SCHEMBL11316555 0.77 PGK1 (0.42) ADORA1KMT2AGRIN2DGRIN3BGRIN1
SCHEMBL8847760 0.77 ADORA1 (0.46) ADORA1KMT2AGAAHTTADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1988091-B1 TRICYCLIC COMPOUNDS KYOWA HAKKO KIRIN CO LTD (JP) 2015-06-10 — — EP disclosed
US-8242151-B2 Tricyclic compounds KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-08-14 — — US disclosed
CN-101646666-A Tricyclic compounds KYOWA HAKKO KOGYO KK JP 2010-02-10 — — CN disclosed
US-20090176760-A1 TRICYCLIC COMPOUNDS KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-07-09 — — US disclosed
EP-1988091-A1 TRICYCLIC COMPOUNDS Kyowa Hakko Kogyo Co., Ltd (JP) 2008-11-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176760-A1 TRICYCLIC COMPOUNDS PPARG, PPARD, PPARA ADORA1 890/4885KMT2A 1525/4885GAA 3391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback